Gentian Diagnostics AS (OSTO:GENTOO) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GENTOO Gentian Diagnostics AS OSTO:GENTOO
60 GF Score
Price kr40.00
GF Value kr53.59
Valuation Modestly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Gentian Diagnostics AS Valuation Rank Related Terms

OSTO:GENTOO
60GF Score
Gentian Diagnostics AS OSTO:GENTOO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gentian Diagnostics AS (OSTO:GENTOO) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr40.00 is trading 25.4% below its estimated GF Value™ of kr53.59. GuruFocus considers Gentian Diagnostics AS to be Modestly Undervalued.

Key valuation signals for OSTO:GENTOO:

  • Valuation Rank:
  • GF Value™: kr53.59 vs. price of kr40.00 (25.4% below fair value)
  • GF Score™: 60/100

No single metric tells the full story. See the OSTO:GENTOO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENT:Norway6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
60GF Score

Get the complete analysis for OSTO:GENTOO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.00
Price
kr53.59
GF Value